Tuberc Respir Dis.
2021 Oct;84(4):338-339. 10.4046/trd.2021.0115.
Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis: Concern to Bedaquiline
- Affiliations
-
- 1Department of Clinical Pharmacy, Program Study of Pharmacy, Hang Tuah University, Surabaya, East Java, Indonesia
- KMID: 2520305
- DOI: http://doi.org/10.4046/trd.2021.0115
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Concurrent, Prolonged Use of Bedaquiline and Delamanid for Multidrug-Resistant Tuberculosis
- Clinical Implications of New Drugs and Regimens for the Treatment of Drug-resistant Tuberculosis
- Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea
- Shorter Oral Regimen for Multidrug Resistant Tuberculosis in South Korea
- Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis: Concern to Bedaquiline: Authors’ Reply
